Stay updated on ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC

Sign up to get notified when there's something new on the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page.
Latest website image capture
Clouds background image

Latest updates to the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page

  1. Check
    yesterday
    No Change Detected
  2. Check
    2 days ago
    No Change Detected
  3. Check
    3 days ago
    No Change Detected
  4. Check
    4 days ago
    Change Detected
    Summary
    The study has expanded to include 22 locations, and the revision has been updated from v2.9.7 to v2.10.0.
    Difference
    0.2%
    Check dated 2024-07-23T14:22:15.000Z thumbnail image
  5. Check
    5 days ago
    No Change Detected
  6. Check
    11 days ago
    Change Detected
    Summary
    The website has been updated to Revision v2.9.7 from v2.9.6.
    Difference
    0.0%
    Check dated 2024-07-16T07:47:25.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.5 to v2.9.6, indicating a recent change in the webpage content.
    Difference
    0.0%
    Check dated 2024-07-02T14:19:56.000Z thumbnail image
  8. Check
    30 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.3 to v2.9.5, indicating a recent revision in the content of the webpage.
    Difference
    0.0%
    Check dated 2024-06-27T10:15:42.000Z thumbnail image
  9. Check
    31 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.9.1 to v2.9.3, indicating a recent revision in the content of the web page.
    Difference
    0.0%
    Check dated 2024-06-26T09:08:27.000Z thumbnail image
  10. Check
    32 days ago
    Change Detected
    Summary
    The value 'Show more Show more Revision: v2.9.0' has been updated to 'Show less MedlinePlus Genetics related topics: Breast cancer MedlinePlus related topics: Breast Cancer Drug Information available for: Eribulin Eribulin mesylate Pembrolizumab FDA Drug and Device Resources Show less Design Details Primary Purpose : Treatment Allocation : N/A Interventional Model : Single Group Assignment Masking : None (Open Label) Arms and Interventions Participant Group/Arm Intervention/Treatment Experimental : Eribulin Mesylate + Pembrolizumab Participants with mTNBC previously treated with 0 (stratum 1) or 1 to 2 (stratum 2) lines of systemic anticancer therapy (cytotoxic or targeted anticancer agents) in the metastatic setting. Drug : Eribulin Mesylate Eribulin Mesylate will be administered as a 1.4 milligram per square meter (mg/m^2) IV (intravenous) infusion on Day 1 and Day 8 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent. Other Names: Halaven, E7389 Drug : Pembrolizumab Pembrolizumab will be administered as a 200 milligram (mg) IV infusion on Day 1 of each 21-day cycle in the presence of clinical benefit until intercurrent illness, unacceptable toxicity, or disease progression occurs, or until the participant withdraws consent. Other Names: Keytruda, MK-3475
    Difference
    76%
    Check dated 2024-06-25T08:35:24.000Z thumbnail image

Stay in the know with updates to ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC

Enter your email address, and we'll notify you when there's something new on the ENHANCE-1 Clinical Trial: Eribulin + Pembrolizumab in mTNBC page.